BioStock: Q2 marked continued progress for Medivir in advanced liver cancer
At the ESMO GI congress in June, Medivir presented greatly improved results for patients with advanced liver cancer in the ongoing phase Ib/IIa study with fostrox in combination with Lenvima. The company is increasingly optimistic about the possibility of launching the first approved drug treatment after first-line treatment of the disease. This is evident from Medivir’s interim report.
– We are now looking forward to presenting detailed and mature clinical data from the study with fostrox at the ESMO Cancer Congress in Barcelona in September, says CEO Jens Lindberg.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/